38
=
Each component of , have demonstrated the
benefits of cardiovascular risk reduction.
45%
ARB/CCB
Among initial combination therapy users, the most frequently
continued combination therapy was ARB/CCB.
Eur J Prev Cardiol. 2020: 6;2047487319900326, J Clin Hypertens. 2008;10: supp.1